Popular on PrZen
- GLADYS Magazine Celebrates their 15 Year Anniversary! - 249
- Music Producer Debuts Riveting Miniseries About a Pro Football Superstar Embroiled in Physical Assault Scandal - 146
- Oil & Gas Workers Association Endorses Allen Mashburn for Lieutenant Governor of North Carolina - 134
- Ironside HR, No. 7 on the 2023 SMU D100 List - 113
- Missbuy Hair Introduction: Breathable Glueless and HD Lace Wigs - 112
- L.A.I. Communications Wins Prestigious Platinum MarCom Award for Excellence in Marketing and Communications - 112
- The New Way of Selling Your House! - 107
- Breaking News - New Music Release - 105
- Descendant of Sojourner Truth designs custom Space Coat !
- It's Fall Planting Season Is Here at TN Nursery
Similar on PrZen
- Dogs at the Dentist: How an unlikely partnership is helping treat dental anxiety
- National Minority Health Association Launches "Equity for All."
- Woburn Dentistry Provides Comprehensive Perio Procedures From One Convenient Location
- Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
- Patriot Urgent Care Opens Much Needed Urgent Care Clinic in Fort Washington
- IntellaTriage Hires Director of Engineering
- Fuel 4 Ever Unveils Innovative Collagen Protein Bars, Revolutionizing Healthy Snacking
- CPR Classes Near Me Expands Services, Now Offering Company and Group AHA CPR Certification Classes in Orlando, FL
- CPR Classes Near Me expands footprint with 20th Location in Denver, Colorado
- Family Braces Experiences Brisk Increase in New Patients This Fall
The ROS1ders Announces Recipients of Inaugural ROS1+ Cancer Innovation Awards
PrZen/33524929
SACRAMENTO, Calif. - PrZen -- The ROS1ders, a global group of patients and caregivers living with ROS1+ cancer, announced the inaugural recipients of The ROS1+ Cancer Innovation Award. Funds were raised through individual contributions by patients and supporters. Each award carries a one-year $75,000 seed grant to fund high-risk, high-reward research projects in ROS1+ cancer.
The recipients are:
"Today's ROS1+ cancer community is grateful our lives are extended by years thanks to biomarker testing and targeted therapy," said Janet Freeman-Daily, co-founder and president of The ROS1ders. "However, the currently approved ROS1 drugs don't work well for everyone. Our patient-driven organization aims to encourage more researchers to study our disease, develop effective treatments, and share their results through open science best practices."
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
● ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer. The incidence is thought to be similar in other types of cancer.
● Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but few other cancers, yet.
● Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
● Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+ NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
The recipients are:
- Lynn Heasley, PhD, and Raphael Nemenoff, PhD, University of Colorado Anschutz Medical Campus — Novel murine ROS1+ cancer models for next-generation therapeutics
This project aims to develop the first genetically engineered mouse that has ROS1+ cancer AND an intact immune system. These mice will enable study of the immune microenvironment surrounding the cancer as well as new treatment options. - Jürgen Wolf, MD, University Hospital Cologne (Universitätsklinikum Köln) – An international consortium to generate high-quality real-world evidence for the optimization of treatment strategies in ROS1-positive lung cancer
This project builds on an existing program in Germany for gathering cancer patient data and samples and expands it to a consortium of countries within the European Union. It's hard to gather enough data on a rare disease like ROS1+ cancer to determine best treatment practices. The database aims to generate evidence that can guide the treatment of patients and improve outcomes.
"Today's ROS1+ cancer community is grateful our lives are extended by years thanks to biomarker testing and targeted therapy," said Janet Freeman-Daily, co-founder and president of The ROS1ders. "However, the currently approved ROS1 drugs don't work well for everyone. Our patient-driven organization aims to encourage more researchers to study our disease, develop effective treatments, and share their results through open science best practices."
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
● ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer. The incidence is thought to be similar in other types of cancer.
● Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but few other cancers, yet.
● Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
● Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+ NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders, Inc
Filed Under: Health
0 Comments
Latest on PrZen
- Lumena, A New Luxury Oceanfront Condominium Takes Flight on Florida's Space Coast
- Dogs at the Dentist: How an unlikely partnership is helping treat dental anxiety
- SSV Network selects Randamu for Distributed Key Generation (DKG) Grant Award
- Lawmato relaunches its virtual consultation app with enhanced features
- MiBOXER Is Exhibiting At Hong Kong International Autumn Lighting Fair
- Beck Properties Group, eXp Realty Expands Service in Southeast Indiana
- Stonely Unleashes Innovative Platform for Homeowners: Design and Order Kitchen Countertops Online with Ease!
- One Million Pages Read in the First Year !!
- Kingston NY-Based Ryan & Ryan Kicks Off its 65th Anniversary Dec. 6 by Underwriting a Chamber of Commerce Mixer Saluting RUPCO
- Tobu Railway's Hosts "Tokyo Downtown Tour: Bamboo Lighting."
- "Street Fighter™ 6" Panel Announced for December 2nd at Los Angeles Comic Con; The Music of Street Fighter 6: A Special Look at the Video Game
- National Minority Health Association Launches "Equity for All."
- Green Office Partner Launches Managed Print Services Program in Canada
- Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion
- The World's No.1 Superstar Rings in 48th Birthday and 25 Years as an Entertainer
- Devart Is the Winner of 2023 New World Report Software and Technology Award
- Unveiling a Secluded Paradise: Beachfront Home on Dog Island, Carrabelle, Florida, Goes to Auction
- SalonInteractive Launches in Square App Marketplace to Provide eCommerce, Marketing & More to Beauty Professionals
- RacquetX Announces Miami Open Experience as Excitement Builds for Landmark 2024 Event
- Dominating Business Intelligence: Informer Tops the BI & Analytics Survey for the Fourth Time